Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
To assess covid and covid vaccine induced thrombosis in Indian patients. One hundred ten subjects who received COVID‐19 vaccine of both genders were included. Parameters such as vaccination history, clinical presentation, treatment administered and vaccine type and dosage, length of time from vaccination date to onset of neuropsychiatric symptoms, clinical manifestations, results of neuro‐imaging, treatment administered, and outcome were recorded. Out of 110 subjects, males were 50 (45.4%) and females were 60 (54.6%). 23 males and 30 females developed COVID‐19 infection. The vaccine type used in subjects was Covishield in 50 and Covaxin in 60. The on set of adverse events after vaccination (in days) after first dose (mean) was 12.4 days and after second dose (mean) was 10.5 days. Adverse events reported were facial diplegia and bulbar palsy in 11, inflammatory myositis in 4 and herpes zoster in 3 patients. COVID‐associated thrombosis was reported in 24 patients. Neuro‐imaging revealed thrombosis in left transverse sinus in 7, sigmoid sinuses in 5 and superior sagittal sinus in 12 patients. Treatment given was Methyl prednisolone in 7, Plasmapheresis in 6, Mycophenolate mofetil in 4 and Rituximab in 7 patients. Outcome was improvement in 16 and death in 8 cases. The difference was significant (p<0.05). Numerous severe neurological side effects have been documented in Indian recipients of the COVID‐19 vaccination. The most common was COVID associated thrombosis. Neuro‐imaging revealed thrombosis in left transverse sinus, sigmoid sinuses and superior sagittal sinus.
How to cite this article:
B. Venkatesh Babu, A. Jenish Babu and R. Ramakrishnan. Three Year Study of Covid and Covid Vaccine Induced Thrombosis in Indian Patients.
DOI: https://doi.org/10.36478/10.59218/makrjms.2023.12.462.465
URL: https://www.makhillpublications.co/view-article/1815-9346/10.59218/makrjms.2023.12.462.465